Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...

BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

After hours: March 14 at 6:50:44 PM EDT Loading Chart for RNA ...

These include difficulty in purifying extremely small amounts of total RNA, a lack of sensitivity, the need to collect samples often because of the very limited amount of RNA available and the ...

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform recommendation. Analyst Price Forecast Suggests 132.29% Upside As of March ...

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for ...

One day after being the underbidder on the session topper, agents John Kimmel and Nick Sallusto were able to snag the most ...

Brook trout may have a genetic trick up their scales when it comes to adapting, with limitations, to heat waves that threaten ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.